Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Withrow > Soft Tissue Sarcomas > Flashcards

Soft Tissue Sarcomas Flashcards

Withrow 2019 - Chapter 22

1
Q

What tissues do STS arise from?

A

Mesenchymal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What have sarcomas been associated with in dogs?

A

Radiation, trauma, foreign bodies, orthopedic implants, and the parasite Spirocerca lupi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Age, breed, sex, and size predilection for STS (dogs)

A

Middle-aged to older
No breed
No sex
Large-breed dogs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Biologic behavior of cutaneous and subcutaneous STS

A

Locally expansive mass growing between fascial planes, but also can be infiltrative. Often surrounded by a pseudocapsule.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Cutaneous and subcutaneous STS recurrence rate and metastatic rate

A

Low to moderate recurrence rate after surgical excision with or without adjuvant RT
Low metastatic rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Likelihood of local recurrence of STS depends on what?

A

Tumor size, degree of infiltration, completeness of histologic excision, histologic grade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Likelihood of metastasis of STS depends on what?

A

Primarily on histologic grade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the STS grading system
- Differentiation
- Mitosis
- Necrosis

A

Grade 1
- Differentiation: resembles normal adult mesenchymal tissue
- Mitosis: 0-9
- Necrosis: None
Grade 2
- Differentiation: Specific histologic subtype
- Mitosis: 10-19
- Necrosis: <50%
Grade 3
- Differentiation: undifferentiated
- Mitosis: >20
- Necrosis: >50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Name STS tumors of fibrous tissues (4)

A

Nodular fasciitis (fibromatosis, pseudosarcomatous, fibromatosis), fibrosarcoma, pleomorphic sarcoma (malignant fibrous histiocytoma), myxosarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Benign non-neoplastic lesion arising from the subcutaneous fascia or superficial portions of the deep fascia in dogs

A

Nodular fasciitis (fibromatosis, pseudosarcomatous, fibromatosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Appearance of nodular fasciitis
- Grossly
- Histologically

A

Grossly - nodular, poorly circumscribed, and very invasive
Histologically - large plump or spindle-shaped fibroblasts in a stromal network of variable amounts of collagen and reticular fibers with scattered lymphocytes, plasma cells, and macrophages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Variant of nodular fasciitis characterized by fibroblast proliferation with a dense reticular fiber network and mucoid material

A

Infantile desmoid-type fibromatosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Nodular fasciitis
- Treatment
- Recurrence
- Metastasis

A
  • Treatment: wide excision usually curative
  • Recurrence: local recurrence possible with incomplete resection
  • Metastasis: do not metastasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Tumor arising from malignant fibroblasts

A

Fibrosarcoma (FSA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Age, breed, sex, and size predilection for FSA

A

Older dogs and cats (Dogs with FSAs were significantly younger than dogs with other histologic subtypes of STS in one study)
No breed or sex predilection (higher predilection for Goldens and Dobermans in one study)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Fibrosarcoma
- Recurrence
- Grade

A
  • More likely to recur after incomplete histologic excision
  • Have higher mitotic rates than other histologic subtypes but are more likely to be low grade
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Age, breed, sex, and site predilection for pleomorphic sarcoma (malignant fibrous histiocytoma)

A

Middle-aged to older dogs
Flat-coated retrievers, Rottweilers, Goldens
No sex predilection
SQ tissues of the trunk and pelvic limbs and spleen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Histologic subtypes of pleomorphic sarcoma (4)

A

Storiform-pleomorphic
Myxoid
Giant cell
Inflammatory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

IHC staining for pleomorphic sarcoma

A

Definitive IHC staining patterns have not been established; typically vimentin positive and CD18 negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Pleomorphic sarcoma
- Grade
- Metastasis

A
  • More likely to be high grade
  • More likely to have metastasis at time of diagnosis compared with other subtypes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Neoplasms of fibroblast origin with an abundant myxoid matrix composed of mucopolysaccharides

A

Myxosarcoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Age and site predilection for myxosarcoma

A

Rare tumor
- Middle-aged to older dogs and cats
- SQ tumors of the trunk and limbs, heart, eye, and brain
- Tend to be infiltrative growths with ill-defined margins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Tumors derived of the different cellular components of vascular wall, excluding the endothelial lining

A

Perivascular wall tumor (PWT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

PWT
- Biologic behavior
- Recurrence

A
  • Less aggressive biologic behavior
  • Significantly lower rates of local recurrence than other histologic subtypes
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Tumors of nerve sheath origin, arising from Schwann cells, perineural cells, or perineural or endoneural fibroblasts.

A

Peripheral nerve sheath tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Most common benign PNST (2)

A

Schwannomas and neurofibromas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

How can malignant PNST be differentiated from PWTs based on IHC staining?

A

Malignant PNSTs stain positive with S-100, vimentin, glial fibrillary acidic protein (GFAP), nerve growth factor receptor, and neuron-specific enolase.
PNSTs have significantly higher Ki67 index than PWTs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

PNST
- Location and biologic behavior
- Recurrence
- Metastasis

A
  • Often subcutaneous,
    poorly circumscribed, adherent to deeper tissues and may infiltrate underlying fascia, muscle, and skin. Tend to be slow growing (often confused with lipomas on PE)
  • Local recurrence common after conservative surgery
  • Modest metastatic rate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Types of PNST of macroscopic nerves (3)

A

Peripheral
Root
Plexus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Clinical signs of plexus PNST

A

unilateral lameness, muscle atrophy, paralysis, and pain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Treatment for PNST

A

surgery, surgery with adjuvant RT, or RT alone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Life-limiting factor for PNST

A

Regardless of histologic grade, local disease usually limits survival before metastasis occurs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Benign tumors of adipose tissue

A

Lipoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Three morphologic types of lipomas

A

Regular
Intermuscular lipomas
Infiltrative lipomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Lipoma
- Age
- Clinical signs
- Location
- Treatment
- Recurrence

A
  • Older dogs
  • Rarely symptomatic, if so are secondary to compression or strangulation
  • Mostly subcutaneous but have been reported in thoracic cavity, abdominal cavity, spinal canal, and vulva/vagina of dogs
  • marginal excision recommended for those that interfere with normal function but majority do not need surgery
  • Surgery usually curative but local recurrence has been noted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Most common location of intermuscular lipomas

A

Caudal thigh of dogs, particularly between the semitendinosus and semimembranosus muscles; also reported in axilla

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

Uncommon tumors composed of well-differentiated adipose cells without evidence of anaplasia

A

Infiltrative lipoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Biologic behavior of infiltrative lipomas

A

Considered benign and do not metastasize but are locally aggressive and commonly invade adjacent muscle, fascia, nerve, myocardium, joint capsule, and bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Treatment options for infiltrative lipomas

A

Aggressive treatment, including amputation, may be necessary for local control. RT can be considered either alone or in combination with surgical excision.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What is the prevalence of FISS?

AH

A

1-4/10K cases
but can be as high as 13-16/10K cases!

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

How did the ratio of FISS to non-ISS changed between 1984 and 1994?

AH

A

Increased from 0.5 to 4.3

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

How long after vaccination, FISS can occur?

AH

A

4 weeks - 10 years

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Are non-adjuvanted vaccines associated with a lower risk of causing FISS compared to adjuvanted vaccines

AH

A

Unclear!
This theory has been proposed but 3 large epidemiologic studies did not provide evidence that aluminum-containing vaccines pose a greater risk of FISS.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What are the local recurrence rates with surgery + radiation therapy for STS?

A

Overall: 20 - 40%
1 year: 70 - 85%
2 year: 60 - 80%
3 year: 57 - 80%
4 year: up to 80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What is the median time to recurrence?

A

14 - 27 mos (412 - >798d)
Grade 1 & 2: >47 mos (>1416d)
Grade 3: 2.5 mos (78d)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

MST for incomplete surgical excision + fRT?

A

Overall: 76 mos (2270d)
1 year: 80-87%
2 year: 72-87%
3 year: 92%
5 year: 76%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

At what mitotic count is a soft tissue sarcoma treated with sx + RT more likely to recur with a shorter OST?

A

MC >9/10 hpf

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

What is the rate of local recurrence following sx + hypofractionated RT?

A

~20%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

What is the progression free interval following sx + hRT?

A

greater than or equal to 23 mos (698d)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

What percentage of patients are free of local recurrence following sx + hRT at 1 year? 2 & 3 years?

A

1 - 80%
2 & 3 - 73%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

What should the timing of hRT post-operatively be to improve outcome?

A

> 4 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What is the progression free survival following hRT by grade?

A

Grade 1: 63.5 mos (1904d)
Grade 2: 19 mos (582d)
Grade 3: 10 mos (292d)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

What is the OST following hRT by grade?

A

Grade 1 & 2: not reached
Grade 3: 31 mos (940d)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

What is the metastatic rate of STS by grade?

A

Grade 1: 0 - 15%
Grade 2: 5 - 25%
Grade 3: 20 - 45%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

How to differentiate FISS from non-ISS by IHC?

AH

A

ISS: positive for PDGFR, EGFR, TGF-β
Non-ISS: negative or faintly positive for these.

Lymphocytes, regional macrophages and ISS neoplastic cells are all positive for PDGFR.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Which gene is expressed more in FISS vs non-ISS?

AH

A

tive in ISSs and not expressed in non–injection-site FSAs.205,206
FeLV and the feline sarcoma virus are not involved in the patho-
genesis of feline ISSs.207

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

There are many similarities between histologic subtypes and
biologic behavior of STSs in cats and dogs.
What are the 3 main exceptions in cats?

AH

A
  1. FISS
  2. Virally induced multicentric FSA
  3. The relative rarity of PNST, SCS, and HS

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

How FISS and non-ISS are different clinically?

AH

A

FISSs are usually large with a rapid growth rate and typically arise from the subcutis at sites consistent with the administration of vaccines and other injections, such as the interscapular region, body wall, and pelvic limbs, whereas non-ISSs are smaller, slower growing, and will often arise from the skin rather thansubcutaneous tissue

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

How to differentiate FISS from non-ISS histologically (other than IHC)?

AH

A

ISSs have histologic features consistent with a more aggressive biologic behavior than non–ISSs, such as:
marked nuclear and cellular pleomorphism
increased tumor necrosis,
high mitotic activity,
multinucleate giant cells
+
the presence of a peripheral inflammatory cell infiltrate consisting of lymphocytes and macrophages

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

In a series of 91 cats with histologically confirmed and graded ISSs, the prevalence of high-grade lesions was substantially higher than reported in dogs,

What percentage of cats in that series were diagnosed with grade III and grade I tumors?

AH

A

~60% grade III
~5% grade I

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

61
Q

Microscopically, areas of transition between inflammation and tumor development are frequently observed in cats with FISS.
What common observation is made about the macrophages present in these areas?

AH

A

The macrophages contain a bluish gray foreign material (consistent with aluminium hydroxide, the common vaccine adjuvant)

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

62
Q

FISSs are histologically similar to what other type of feline tumor?

AH

A

Sarcomas arising from traumatized eyes

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

63
Q

CT and MRI are both very sensitive for the detection of the peritumoral extent of cats with suspected FISSs.
What percentage of these peritumoral lesions are neoplastic?

AH

A

~40%
Up to 60% of these peritumoral lesions are non-neoplastic when examined histologically.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

64
Q

Why excisional biopsy of suspected FISSs are not recommended?

AH

A

Increased risk of local recurrence
Significant decrease in DFI and ST.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

65
Q

What is the MST for dogs with STS with Sx alone or Sx + adjuvant RT?

AH

A

The majority of studies can’t report MST because only 10-30% of dogs die after curative-intent treatment for STS.
Sx alone: 1013 -1796d (~ (2y9mo-5y1mo)
Sx + RT: 2270d (6y3mo)

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

66
Q

What are the 1-, 2-, 3-, 4-, and 5-yr survival probablities for dogs with STS treated with curative intent?

AH

A

1-yr: 80% to 94%
2-yr: 72% to 87%
3-yr: 61% to 81%
4-yr: 81%
5-yr: 76%

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

66
Q

What is the impact of tumor invasiveness on tumor-related deaths in dogs with STS?

AH

A

Dogs with grossly invasive and fixed STSs have a 5-fold increased risk of tumor related deaths, presumably because of greater difficulty in achieving complete excision of their STSs.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

67
Q

What is the impact of surgical approach (curative vs non-curative intent) on MST of dogs with STS?

AH

A

Curative-intent: 1306 d (~3y7mo)
vs.
Non-curative intent: 264d (~9mo)

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

68
Q

What is the impact of completeness of excision on MST in dogs with STS?

AH

A

Complete excision: 1306d (~3y7mo)
vs.
Incomplete excision: 657d (~1y10mo)

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

69
Q

What is the impact of **local tumor recurrence **on tumor-related deaths in dogs with STS?

AH

A

5X risk of tumor-related death in dogs with recurrence vs. without.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

70
Q

What is the impact of tumor necrosis on tumor-realted deaths in dogs with STS?

AH

A

3X more likely when >10% necrosis was present.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

71
Q

What is the impact of >20 MF/10 HPF on tumor-realted deaths in dogs with STS?

AH

A

3X more

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

72
Q

What is the MST for dogs with STS, based on MF/10 HPF?
<10, 10-19, >20

AH

A

<10: 1444d (~3y11mo)
10-19: 532d (~1y5mo)
>20: 236d (~7mo)

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

73
Q

Impact of histologic grade on MST in dogs with STS, treated with RT?

AH

A

grade I: MST not reached
grade II: >1461d (4 years)
grade III: 78d (3 mos)

Incompletely excised STS + fractionated RT, grade III:
135d
vs.
Incompletely excised STS + hypofractionated RT, grade I and II:
MST not reached.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

74
Q

Impact of AgNOR (below and above the median AgNOR scores) on MST and survival ratesfor dogs with STS?
Chances of dying from tumor with increased AgNOR score?

AH

A

AgNOR<median: >1188d (3y1mo), 76%
vs
AgNOR>median: >1306d (~3y7mo), 53%

77X more likely

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

75
Q

Impact of Ki67 on MST and survival rates in dogs with STS?

AH

A

Ki67>median: 657d (22 mos)
Ki67<median: >1188d (40 mos) , 94% survival

Increased Ki67: 12X more likely to die as a result of their dz

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

76
Q

Overall metastatic rate and median time to metastasis in dogs with STS?

AH

A

0-31%
median time to metastasis of 230 to 365 days (~8mo-1yr)

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

77
Q

What are the factors that increase the risk of metastasis in dogs with STS, and what is the impact of each one?

AH

A
  1. Histologic grade:
    grade I: 0-13%
    grade II: 7-27%
    grade III: 22-44%
  2. > 20 MF/10HPF: X5 more likely
  3. More likely in pleomorphic and undifferentiated sarcomas compared with FSAs, PNSTs, myxosarcomas, and liposarcomas
  4. In one study, no dog with a STS at or below the level of the elbow or stifle
    developed metastatic disease
  5. Percentage of necrosis
  6. Local tumor recurrence

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

78
Q

What is the overall local recurrence rates in dogs with STS?
After wide resection
After marginal resection
After incomplete histologic excision + fractionated RT
After incomplete histologic excision + hypofractionated RT

AH

A

After wide resection: 0-5%
After marginal resection: 11-29%
After incomplete histologic excision + fractionated RT: 17-37%
After incomplete histologic excision + hypofractionated RT: 18-21%

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

79
Q

What chemotherapy protocols improve local tumor control for canine STS?

A

Metronomic cyclophosphamide
Intralesional chemotherapy

80
Q

What is the likelihood of local recurrence after surgery + intralesional chemotherapy?

A

15 - 30%

81
Q

What is the complication rate after treatment with Sx + intralesional chemotherapy?

A

Wound complications - 50 - 85%

82
Q

What is the likelihood of complete histopathologic excision for FISS with 2-3 cm lateral margins? 4-5 cm lateral margins?

A

2-3 cm: <50%
4-5 cm: 95-97%

83
Q

What is the percentage of local recurrence based on histopathologic margins for FISS?

A

Complete: 15 - 20%
Incomplete: 60 - 70%

84
Q

What is the 1 and 2 year disease free rate for FISS with 2-3 cm margins?

A

1 year: 35%
2 year: 9%

85
Q

What is the 3 year disease free rate for FISS with 5 cm margins?

A

85%

86
Q

What is the overall likelihood of recurrence with Sx + RT for FISS? With complete histologic margins? Incomplete?

A

Overall: 30 - 45%
Complete: 40%
Incomplete: 30%

87
Q

What is the DFI for FISS with Sx + RT?

A

13 - 37 mos
Complete: 23 - 33 mos (700 - 986d)
Incomplete: 4 - 10 mos (112 - 292d)

88
Q

What is the time to first recurrence for FISS treated with Sx + RT with complete histologic margins? Incomplete?

A

Complete: 11 - 14 mos (325 - 419d)
Incomplete: ~3 mos (79d)

89
Q

DFI and dz-free rates for dogs with STS, treated with Sx alone vs incomplete excision + fractionated RT vs. incomplete excision + hypofractionated RT.

AH

A

The DFIs and local tumor control rates are also similar between the different treatment options,
Sx. alone:
DFI: 368-637d to not reached.
1-yr dz-free: 89-93%
2-yr dz-free: 78-82%
e-yr dz-free: 66-76%

Incomplete excision + fractionated RT:
DFI: 412 or >798d
1-yr dz-free: 71-84%
2-yr dz-free: 60-81%
3-yr dz-free: 57-81%
4-yr dz-free: up to 81%

Incomplete excision + hypofractionated RT:
DFI 698d to not reached
1-yr dz-free: 81%
2-yr dz-free: 73%
3-yr dz-free: 73%

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

90
Q

What are prognostic factors for recurrence of FISS?

A

tumor size, Sx dose/aggressiveness, complete histologic margins, grade

91
Q

What are the metastatic rates for FISS based on grade?

A

Grade 1: 0 - 17%
Grade 2: ~20%
Grade 3: 20 - 100%
Overall: 0 - 25%

92
Q

What is the MST for FISS with Sx 4-5 cm lateral, 2 fascial planes deep?

A

27 - 30 mos (804 - 901d)

93
Q

What is the MST for FISS with less aggressive Sx?

A

13 - 20 mos (>395 - 608d)

94
Q

What is the MST for Sx + RT for FISS? Survival rates for 1, 2, and 3 years?

A

Overall: 17 - 43.5 mos (520 - 1307d)
1 year: 60 - 85%
2 year: 40 - 70%
3 year: 30 - 70%

95
Q

What are the prognostic factors for MST for FISS?

A

anemia, tumor size, treatment type, histologic subtype, mitotic rate, local tumor recurrence, metastasis

96
Q

What is the PCV cutoff for impact on MST for FISS?

A

25%
MST PCV <25%: 10 mos (308d)
MST PCV >25%: 25 mos (760d)
PCV <25% SR: 1 year - 40%, 2 year - 24%
PCV >25% SR: 1 year - 72%, 2 year - 50%

97
Q

What are poor prognostic factors for local tumor control in dogs with STS?

AH

A

Large tumor (>5cm)
Infiltrative tumors
Tumors in locations other than limbs at or below the elbow or stifle
Histologic subtypes
Grade III STS
Incomplete surgical margins

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

98
Q

How does tumor size impact prognosis with surgery alone for FISS?

A

MST
<2 cm: 21 mos (643d)
2-5 cm: 19 mos (558d)
>5 cm: 13 mos (394d)

99
Q

What is the impact of preoperative RT on MST for FISS? Postoperative RT?

A

Preop: 10 mos (310d)
Postop: 23.5 mos (705d)

100
Q

What is the 1 and 2 year survival rate with preoperative RT for FISS? Postop?

A

Preop: 1 year - 40%, 2 year - 30%
Postop: 1 year - 70%, 2 year - 50%

101
Q

Which histologic subtype of FISS has the worst prognosis?

A

MFH (malignant fibrous histiocytoma) - MST 10 mos (290d) vs ~21 mos for FSA and PNST

102
Q

What is the MST for FISS with a mitotic rate >20?

A

33 mos (994d)

103
Q

What is the MST for FISS that had recurrence? Without recurrence?

A

(+) 11 - 17 mos (327 - 499d)
(-) 37 - 49 mos (1098 - 1461d)
2 year survival rate: (+) 40%, (-) 75%

104
Q

What is the MST for FISS with and without metastasis?

A

With: 5.5 - 13 mos (165 - 388d)
Without: 31 - 51 mos (929 - 1528d)

105
Q

What is the 3-2-1 rule for FISS?

A

Investigate if:
3 - Mass present >/= 3 mos after vax
2 - Mass is > 2cm diameter
1 - Increase in size > 1 mo after vax

106
Q

Where are the appropriate sites for vaccination for cats for each vaccine?

A

Rabies: distal RPL
FeLV: distal LPL
All other: R shoulder

107
Q

Local recurrence grade III STS vs low-grade?

AH

A

6X greater risk of local recurrence

In one study of 236 dogs with subcutaneous STSs
treated with excisional biopsy, the local recurrence rate was 0% for
STSs excised with complete histologic margins and 19% overall
for incompletely excised STSs.
The recurrence rate for incom-
pletely excised grade I, II, and III STSs was 7%, 34%, and 75%
(three of four) respectively.

Withrow 2019 - Ch 22 - Soft Tissue Sarcomas

108
Q

Minimum recommended surgical margins of STS

A

2-3cm lateral and one fascial layer deep to the tumor

109
Q

Dogs with complete incision are ____ times less likely to have local tumor recurrence compared with dogs with incompletely excised STS

A

10.5x

110
Q

Local recurrence rate for an incompletely excised grade I STS

A

7%

111
Q

Local recurrence rate for an incompletely excised grade II STS

A

34%

112
Q

Bleomycin electrochemotherapy for incompletely excised STS - what is the overall local recurrence rate? Mean time to recurrence?

A

36%, 730 days

113
Q

True to false, ISSs are well encapsulated tumors

A

false (poorly encapsulated and infiltrative along fascial planes)

114
Q

Recommended surgical margins for ISS

A

5cm lateral and two fascial layers deep

115
Q

Median time to first recurrence after marginal resection of ISS compared to wide to radical

A

79 days vs. 325 to 419 days

116
Q

When using 2 to 3 cm surgical margins for ISS in cats, complete resection is achieved in what percent of cats? What are the 1 and 2 year disease free rates?

A

<50% of cats, 35% and 9%

117
Q

What cells do liposarcomas arise from?

A

lipoblasts, lipocytes

118
Q

What are metastatic sites of liposarcoma?

A

lungs, liver, spleen, bone

119
Q

What is the metastatic rate of liposarcomas (high/moderate/low)?

A

low

120
Q

Where are liposarcomas commonly found?

A

SQ, especially along the ventrum and extremities

121
Q

What cytological stain can help to differentiate between liposarcomas and other STS?

A

Oil Red O

122
Q

How can CT differentiate liposarcomas from regular and infiltrative lipomas?

A

liposarcomas appear as mixed-attenuating, heterogenous, multinodular, and contrast enhancing masses

123
Q

What is the prognosis for liposarcoma w/surgical excision?

A

good, MST after wide excision is 1,188 days

124
Q

What is MST for liposarcoma that is marginally excised? Incisional biopsy?

A
  1. 649 days
  2. 183 days
125
Q

What cell type do rhabdomyosarcomas originate from?

A

myoblasts or primitive mesenchymal cells

126
Q

What sites are rhabdomyosarcomas most likely to arise from in dogs?

A

urinary bladder, retrobulbar musculature, larynx, tongue, myocardium

127
Q

What is the metastatic potential of rhabdomyosarcoma?

A

low to moderate,
metastatic sites include lungs, liver, spleen, kidneys, adrenal glands.

128
Q

What are the histological classifications of rhabdomyosarcoma?

A

embryonic, botryoid, alveolar, pleomorphic

129
Q

What IHC staining may be necessary to diagnose rhabdomyosarcoma?

A

vientin, skeletal muscle actin, myoglobin, myogenin, myogenic differentiation (MyoD)

130
Q

What is the metastatic rate for boytroid rhabdomyosarcoma?

A

27%

131
Q

What is the metastatic rate for embryonal and alveolar rhabdomyosarcoma?

A

50%

132
Q

Metastatic disease in dogs with rhabdomyosarcoma is more common in what age group?

A

<4 years

133
Q

What cell does lymphangiosarcoma arise from?

A

lymphatic endothelial cells

134
Q

Describe the appearance of lymphangiosarcoma?

A

soft, cystic like, edematous mass, usually in the subcutis. Most often associated with extensive edema or nonhealing, discharging wounds

135
Q

What IHC markers can be used to differentiate between lymphangiosarcoma and hemangiosarcoma?

A

CD31, factor VIII-related antigen, lymphatic vessel endothelial receptor 1 (LYVE-1), propsero-related homeo box gene-1 (PROX 1)

136
Q

What is the MST for dogs with lymphangiosarcoma with no treatment vs surgery vs surgery/RT/chemo?

A

No treatment: 168 days
Sx alone: 487 days
Sx/RT/chemotherapy: 574 days

137
Q

What is a malignant mesenchymoma?

A

STS comprising a fibrous component with two or more different vvarieties of other types of sarcomam

138
Q

What is the growth rate of malignant mesenchymoma?

A

slow

139
Q

What is the MST for dogs with splenic mesenchymoma?

A

12 months

140
Q

What is the cytologic accuracy of correctly diagnosing STS?

A

63-97%

141
Q

What percentage of preoperative biopsies are successful at determining histologic grade of STS?

A

59%
underestimated grade in 29%
overestimated in 12%

142
Q

1 and 2 year tumor control for RT alone (50gy)

A

50%, 33%

143
Q

Median PFI for hypofractionated RT in macroscopic STS

A

155-419 days

144
Q

Prognostic factors for median PFI for hypofractionated RT

A

Tumor location - significantly better for limbs (466 days) than head or trunk (110 days)
Previous surgeries - dogs treated with more than one surgery had a significantly decreased median PFI (105 days) compared with dogs treated with one or no surgery (420 days)

145
Q

MST after hypofractionated RT for macroscopic
STS

A

206 to 513 days

146
Q

What factor has a significant effect on MST for hypofractionated RT for macroscopic STS?

A

location - STSs located on the limbs (579 days)
having a better outcome than those on the head (195 days) or trunk (190 days).

40% of dogs in this study were also treated with metronomic chemotherapy

147
Q

Rationale for preoperative RT for STS

A

(1) the radiation field is smaller because, after surgery, the entire surgical site must be included in the field plus a margin of normal tissue and this may contribute to local toxicity
(2) a large number of peripheral tumor cells are inactivated (with reduced contamination of the surgical site)
(3) tumor volume reduction may make surgical resection less difficult

Withrow (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions